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AS (Apert syndrome) is a congenital disease composed of
skeletal, visceral and neural abnormalities, caused by dominant-
acting mutations in FGFR2 [FGF (fibroblast growth factor)
receptor 2]. Multiple FGFR2 splice variants are generated through
alternative splicing, including PTC (premature termination
codon)-containing transcripts that are normally eliminated via the
NMD (nonsense-mediated decay) pathway. We have discovered
that a soluble truncated FGFR2 molecule encoded by a PTC-
containing transcript is up-regulated and persists in tissues of
an AS mouse model. We have termed this IIIa–TM as it arises
from aberrant splicing of FGFR2 exon 7 (IIIa) into exon 10
[TM (transmembrane domain)]. IIIa–TM is glycosylated and can
modulate the binding of FGF1 to FGFR2 molecules in BIAcore-
binding assays. We also show that IIIa–TM can negatively regulate
FGF signalling in vitro and in vivo. AS phenotypes are thought
to result from gain-of-FGFR2 signalling, but our findings suggest
that IIIa–TM can contribute to these through a loss-of-FGFR2
function mechanism. Moreover, our findings raise the interesting
possibility that FGFR2 signalling may be a regulator of the NMD
pathway.
Key words: Apert syndrome, fibroblast growth factor receptor
2 (FGFR2), mRNA splicing, nonsense-mediated decay (NMD)
pathway.
INTRODUCTION
Loss-of-function studies have demonstrated that FGF (fibroblast
growth factor) signalling is a critical mediator of cellular
interactions that underlie tissue development, repair and
homoeostasis. For example, the growth of lungs and limbs is
arrested in Fgf10-null embryos and adult Fgf23-deficient mice
develop hyperphosphataemia [1,2]. However, subtle defects can
also arise from partial-loss- or gain-of-FGF signalling, suggesting
that the level of FGF signal perceived by target cells is also
important [3–5]. This is exemplified by AS (Apert syndrome)
and Pfeiffer syndrome, which are hallmarked by a host of
skeletal, visceral and neural defects arising from dominant-acting
mutations in FGFR1 (FGF receptor 1) and FGFR2 [6]. Therefore
identifying the set of factors and mechanisms that regulate the
dynamics of FGF signalling will further our understanding of
growth factor signalling in developmental and disease processes.
The mammalian FGF signalling system comprises 18 FGF
ligands and four transmembrane FGFRs (FGFR1–FGFR4), and
can operate both in a morphogen and a threshold-dependent
signalling manner [7–9]. Formation of a trimeric complex of
FGFs, sulfated proteoglycans and membrane-anchored FGFR
molecules results in the recruitment of intracellular adaptor
proteins by the activated FGFRs and signal transduction to the
nucleus via the MAPK (mitogen-activated protein kinase), PI3K
(phosphoinositide 3-kinase) or PLC (phospholipase C) signalling
pathways. Typically, FGF signalling induces changes in gene
expression and/or cytoskeletal reorganization to regulate multiple
aspects of cell behaviour and fate. The level and threshold
of FGF signalling is modulated intracellularly through the
activity of proteins such as Sprouty, MKP3 (MAPK phosphatase
3), Spred and Sef, and by the synergistic or antagonistic
effects of other signalling pathways, including Notch, Wnts,
BMPs (bone morphogenetic proteins), Hedgehogs etc. [5,10].
Extracellular regulation, by contrast, is dependent mostly on
the bioavailability of FGFs and FGFRs, as well as factors that
modulate their interactions such as FLRTs (fibronectin leucine-
rich transmembrane proteins) and Klotho [11,12].
FGFR molecules are typically composed of two or three
extracellular Ig-like domains (Ig-I, Ig-II and Ig-III) harbouring the
ligand-binding sites, a single-pass TM (transmembrane) domain,
an intracellular juxtamembrane domain, and a split tyrosine
kinase domain. Alternative splicing of FGFR transcripts generates
multiple receptor isoforms and contributes to the functional
diversity of FGF signalling [7,13]. For example, the VT + or
VT − isoforms of FGFR1, which harbour or lack amino acids
Val428 and Thr429 in the juxtamembrane domain respectively,
engage different signalling pathways [14]. Moreover, the so-called
‘IIIb’ and ‘IIIc’ spliced isoforms of FGFR1–FGFR3 are formed
through alternative usage of exons 8 and 9, which encode the
C-terminal half of Ig-III [15], i.e. exon 7 (IIIa)–8 (IIIb)–10 (TM)
or exon 7 (IIIa)–9 (IIIc)–10 (TM) splice variants. These isoforms
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play critical roles in the paracrine cross-talk between epithelial
and mesenchymal cells, since IIIb isoforms are predominant in the
former and activated by mesenchymally produced FGF ligands
(FGF3, FGF7, FGF10 and FGF22), whereas the IIIc receptor
isoforms are expressed by mesenchymal (and neural) cells and
are activated by a different set of FGFs (FGF2, FGF4, FGF8,
FGF9 and FGF18) produced by epithelial cells [16].
Less clear is the biological significance of soluble FGFR
isoforms. These include a molecule that specifically lacks the
TM domain, or truncated receptors that harbour Ig-II and Ig-IIIa,
with or without fusion to the first three amino acids of the TM
domain or non-coding intronic sequences [7,17,18]. Some of these
truncated receptors are encoded by PTC (premature termination
codon)-containing transcripts [7], and are probably eliminated by
the NMD (nonsense-mediated decay) pathway machinery [19].
Through gene targeting in ES (embryonic stem) cells, we have
previously generated mice with an AS-type FGFR2 mutation
[20]. In these, as in some patients, a heterozygous deletion
of FGFR2 exon 9 (IIIc) (i.e. FgfR2-IIIc+ /) results in the
aberrant co-expression of FGFR2-IIIb and FGFR2-IIIc isoforms
in mesenchymal and neural cells [21,22]. Consequently, the
affected tissues become promiscuously responsive to a broader
set of FGF ligands and a gain-of-FGFR2 function ensues. We
validated this mechanism by showing that much of the AS-like
phenotypes in FgfR2-IIIc+ / mice can be rescued merely by
knocking down the levels of FGF10, a key FgfR2-IIIb-activating
ligand [23].
We now report that FgfR2-IIIc+ / tissues additionally harbour
a PTC-derived truncated FGFR2 molecule that we term ‘IIIa–
TM’. IIIa–TM arises from direct splicing of exon 7 (IIIa) into
10 (TM) to encode a molecule that harbours the Ig-I, Ig-II and
the N-terminal half of Ig-III (IIIa) domains fused to the first
three amino-acids of TM. We have explored the biochemical
properties of IIIa–TM and find that it has some ligand-binding
capacity. Moreover, IIIa–TM is capable of attenuating basal FGFR
signalling in vitro and in vivo, and influences the trafficking of
endogenous FGFR2 molecules. Our findings suggest that IIIa–TM
escapes NMD and acts as a negative regulator of FGFR signalling
to cause or contribute to the severity of phenotypes in AS, which
were otherwise thought to arise solely through gain-of-FGFR2
activity.
MATERIALS AND METHODS
Animals and tissue source
FgfR2-IIIcfloxed/ + and PGK (phosphoglycerol kinase)-Cre mice
were used to derive the FgfR2-IIIc+ / mutant mice/tissues, as
described previously [20,23]. All mice were bred and maintained
on C57BL background in accordance with Home Office licences
and local regulations governing animal welfare and ethics.
Detection, isolation and cloning of IIIa–TM
RNA was isolated from brains of newborn wild-type or
FgfR2-IIIc+ / (mutant) mice using Tri reagent (Sigma),
and subjected to two-step RT (reverse transcription)–PCRs
using Ready-to-Go beads (Amersham Pharmacia) and cycle
conditions described previously [20,24]. The IIIa–TM transcript
(Figure 1A) was detected using Primers P1 (5′-CCCATCCT-
CCAAGCTGGACTGCCT-3′) and P2 (5′-GCTTGGTCAGC-
TTGTGCACAGCTGG-3′). ‘Full-length’ FGFR2-IIIa–TM was
amplified using an NdeI-tagged primer P3 (5′-AGTTT-
AGTTGAGGATACCACTTTAG-3′) in conjunction with an NotI-
Figure 1 Structure and detection of IIIa–TM in FgfR2-IIIc+ / (mutant) mice
(A) Schematic representation of the FgfR2 locus and the aberrant splicing of exon 7 (IIIa)
into 10 (TM) which yields a PTC-containing transcript and a truncated protein with eight
potential glycosylation sites (black circles). Chequered box, secretory signal sequence; bold
line, contribution of TM exon; star, termination codon. (B, C). Detection of IIIa–TM transcript
and protein in the mutant but not wild-type (WT) brain. (B) The use of Primers P1 and P2
(positions indicated in A) in RT–PCRs generated two products from mutant RNA. Note, neural
tissue expresses the IIIc isoform of FGFR2 [24]. (C) The detergent-soluble fractions of mutant
brain tissue resolved on two-dimensional gels and immunoprobed with anti-FGFR2 antibodies.
Two major 55 kDa products (pIs 5.1 and 6.3) and a minor 120 kDa (pI 4.3) product are evident.
No spots were detected in blots of wild-type tissue.
tagged primer P4 (5′-TCACAGGCGCTTCAGGACCTTG-3′).
Products were sequenced using forward or reverse complements
of primers P1 and P5 (5′-CGTGATCAGTTGGACTAA-
GGATGG-3′; nucleotides 815–835 of FgfR2; GenBank®
accession number, NM_010207) (see Supplementary Figure S1
at http://www.BiochemJ.org/bj/436/bj4360071add.htm). A
0.9 kb recombinant IIIa–TM was generated by primers P2 and
P3, gel-purified and cloned into a 7.9 kb ires-Topaz-pEF-BOS
plasmid, downstream of sequences encoding the human FGFR2
secretory signal sequence, IgG-Fc and a 3C-protease-sensitive
site (see Supplementary Figure S2 at http://www.BiochemJ.
org/bj/436/bj4360071add.htm). To examine the distribution
of native IIIa–TM protein, lungs or brains of wild-type and
mutant newborn mice were triturated through a 19G gauge
needle and protein was extracted by incubation for 30 min
at 4 ◦C in 500 μl of RIPA buffer (10 mM Tris/HCl, pH 7.4,
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1 mM EGTA, 150 mM NaCl, 0.1% SDS, 1% Nonidet P40,
0.5% sodium deoxycholate, 1 mM PMSF and 1 mM Na3VO4)
containing protease inhibitor cocktail (Roche). Tissue lysates
were cleared by centrifugation (20800 g for 60 min at 4 ◦C) and
protein concentrations were determined by Coomassie assay
(Pierce).
Maintenance and transfection of cell lines
HEK-293T cells (human embryonic kidney-293 cells expressing
the large T-antigen of simian virus 40) and Cos7 cells
were maintained at 37 ◦C in a humidified atmosphere of
5% CO2 in DMEM (Dulbecco’s modified Eagle’s medium),
supplemented with 10% FBS (fetal bovine serum), 2 mM L-
glutamine, 1 mM sodium pyruvate, 0.2 unit/ml penicillin and
0.1 mg/ml streptomycin. Plates containing HEK-293T cells at
70% confluency were transiently transfected using the calcium
phosphate precipitation method overnight with plasmid DNA (30,
60 or 300 μg) diluted in 2 M CaCl2 and 2× HBS (1.2% Hepes,
1.6% NaCl and 0.04% Na2HPO4, pH 7.12). Cells were then
washed with serum-free medium and maintained in the same
medium or Ultracho medium (Biowhittaker).
Antibodies
The primary antibodies used were: sheep anti-FGFR2(Nt)
(N-terminal) (1:2000–10000 dilution; [25]), rabbit anti-Bek
(cytoplasmic FGFR2, 1:500–1000 dilution; C-17, Santa Cruz
Biotechnology), mouse anti-ERK (extracellular-signal-regulated
kinase) and anti-phospho-ERK (1:1000 and 1:2000 dilution
respectively; Cell Signaling Technology), mouse anti-Lamp2
(lysosome-associated membrane protein 2) (1:50 dilution;
Abcam), and HRP (horseradish peroxidase)-conjugated goat anti-
(human Fc) (1:10000 dilution; Pierce). The secondary antibodies
used were HRP-conjugated anti-(mouse Ig), anti-(rabbit Ig)
(1:5000 dilution; Amersham Biosciences) and anti-(sheep Ig)
(1:4000 dilution; The Binding Site), FITC-conjugated anti-(rabbit
Ig) (1:300 dilution) and Texas Red-conjugated anti-(mouse Ig)
(1:200 dilution; Molecular Probes).
Immunodetection and quantification of FGFR2 and Lamp2
co-localization
Cos7 cells were grown on glass coverslips and transfected with
FGFR2 using Genejuice (Invitrogen). At 48 h later, cells were
fixed with 4% paraformaldehyde (10 min), permeabilized with
ice-cold methanol and re-hydrated in PBS. After incubation for
1 h in PBS/4% BSA, the cells were exposed to anti-Lamp2 and
anti-Bek antibodies for 1 h. Coverslips were then washed in PBS
and incubated with the relevant secondary antibodies for 1 h,
washed in PBS/0.1% Tween 20 and mounted using Mowiol
medium. Images of immunolabelled cells were captured using
a confocal microscope (Leica), processed in Adobe Photoshop
and merged using ImageJ. To quantify the co-localization of
FGFR2 and Lamp2, 15 random images from different treatments
across two different experiments were analysed and a co-efficient
was determined using ZEN 2009 software. Mean (+−S.E.M.)
values were subjected to analysis using a Student’s t test.
A one-way ANOVA indicated no variance with respect to
time of FGF2 stimulation in the absence of IIIa–TM (see
Figure 5A for paradigm), but a significant difference in its
presence (*P < 0.05 and ***P < 0.0001). Dunnett’s Multiple
comparison test also confirmed a significant abrogation of
FGFR2/Lamp2 co-localization in the presence of IIIa–TM-
only.
Immunoprecipitation of FGFR2
Protein was extracted from pellets of transiently transfected
HEK-293T cells by incubation for 30 min in a lysis buffer
(10 mM Tris/HCl, pH 8, 2.5 mM MgCl2, 5 mM EGTA, 0.5%
Triton X-100, 1 mM Na3VO4 and 50 mM sodium fluoride)
containing protease inhibitor cocktail (Roche). After removing
cell debris, the Triton X-100-insoluble fraction was isolated
by centrifugation, and FGFR2 was immunoprecipitated from
the supernatant with 3.5 μg of anti-Bek antibodies for 1 h at
4 ◦C. Immunocomplexes were captured with a 50% Protein A–
Sepharose slurry for 30 min at 4 ◦C, and samples were washed
twice with ice-cold hcTBST (100 mM Tris/HCl, 1.5 M NaCl
and 0.05% Tween 20, pH 7.4), followed by ice-cold TE buffer
(10 mM Tris/HCl and 1 mM EDTA, pH 7.5). The resultant
samples were boiled for 5 min and subjected to SDS/PAGE and
immunoblotting analyses.
SDS/PAGE and protein detection
Proteins were separated by SDS/PAGE and transferred on to
nitrocellulose membranes (Protran BA85; Schleicher & Schuell)
using a Biometra semi-dry transfer system at 5 mA/cm2 of gel
for 25 min. Membranes were blocked overnight at 4 ◦C with
TBST (20 mM Tris/HCl, 140 mM NaCl and 0.1% Tween 20,
pH 7.4) containing 5% BSA and then incubated for 1 h at
room temperature (22 ◦C) with the relevant primary antibodies.
Secondary antibodies were applied for 1 h at room temperature
and, following washes in TBST, immunoreactive bands were
detected with ECL (enhanced chemiluminescence) reagents
(Pierce). Where necessary, membranes were stripped in 0.1 M
glycine (pH 2.5), washed sequentially in TBST and TBST/5%
BSA and re-probed overnight at 4 ◦C.
Purification of Fc-tagged proteins
3CFc, IIIa–TM–3CFc, FGFR2-IIIb–3CFc and FGFR2-IIIc–3CFc
proteins were harvested from HEK-293T cells or their conditioned
medium 24 h (48 h for IIIa–TM) after transfection with the
relevant plasmids [25]. 3CFc-tagged proteins were purified by
gravity flow over a Protein A–Sepharose fast-flow column
equilibrated previously with MT-PBS (150 mM NaCl, 16 mM
Na2HPO4 and 4 mM NaH2PO4, pH 7.4). Columns were then
washed successively with MT-PBS/1% Triton X-100, MT-PBS
alone and finally 50 mM Tris/HCl (pH 8) and 150 mM NaCl
solution. Proteins were eluted from the column with 0.1 M
glycine, pH 3, and dialysed overnight at 4 ◦C. To obtain cleaved
recombinant IIIa–TM, the column was washed with TNED
[50 mM Tris/HCl, pH 8, 150 mM NaCl, 10 mM EDTA and 1 mM
DTT (dithiothreitol)] and treated overnight at 4 ◦C with 10 μg of
3C protease. Cleaved IIIa–TM was then dialysed into PBS.
PNGase-F (peptide N-glycosidase F) treatment
Purified IIIa–TM protein (1 mg) was boiled for 10 min
in a solution containing 50 mM Tris/HCl, pH 8, 150 mM
NaCl, 10 mM EDTA, 1 mM DTT, 0.5% SDS and 1% 2-
mercaptoethanol, and treated for 16 h at 37 ◦C with 5 units
of PNGase-F (New England Biolabs) in a solution of 50 mM
Na2HPO4 (pH 7.5) and 1% Nonidet P40.
Two-dimensional gel electrophoresis
A portion (100 mg) of tissue-extracted protein or 900 ng
of recombinant IIIa–TM protein was mixed with 125 μl of
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rehydration buffer (8 M urea, 2% CHAPS, 20 mM DTT, 0.5%
IPG buffer and a trace of Bromophenol Blue) and loaded into
a strip holder. An IPG drystrip (7 cm, pH 4–7 immobilized
linear gradient; Amersham Pharmacia) was overlaid on to the
rehydration buffer containing the sample and rehydrated overnight
at 20 ◦C. Optimal IEF (isoelectric focusing) was carried out using
an IPGphor step-n-hold and the following protocol: 500 V for 500
Vh, 1000 V for 1000 Vh and 8000 V for 16000 Vh, all at 20 ◦C.
Strips were then immediately processed for SDS/PAGE or stored
at − 70 ◦C until required.
For SDS/PAGE, IEF strips were equilibrated for 20 min at
a time with equilibration buffer 1 (50 mM Tris/HCl, pH 8.8,
6 M urea, 30% glycerol, 2% SDS, 60 mM DTT and a trace
of Bromophenol Blue), followed by equilibration buffer 2 (same
as buffer 1, but DTT was replaced with 25 mg/ml iodoacetamide).
Drystrips were sealed into wells (0.5% agarose in running buffer)
and samples were then resolved on vertical gels by SDS/PAGE
at 110 V for 10 min, followed by 200 V for 30 min. Protein
spots were visualized by chemiluminescence after transfer to
nitrocellulose, as described above.
SPR (surface plasmon resonance) analysis
All protein interactions were measured using a BIAcore 2000.
3CFc-tagged proteins were immobilized in 10 mM sodium
acetate, pH 4.5, on to a research-grade C1 sensor chip (BIAcore),
according to the manufacturer’s instructions, at a flow rate of
10 μl/min. Proteins were immobilized to similar levels [∼1000
RUs (response units) above the pre-injection baseline; ∼400 RUs
for 3CFc owing to a difference in molecular mass] and the excess
carboxy groups were then blocked by an injection of 70 μl of 1 M
ethanolamine, pH 8.5. Binding experiments were performed in
HBS-EP (0.01 M Hepes, pH 7.4, 0.15 M NaCl, 3 mM EDTA and
0.005% surfactant P-20) (BIAcore) at a flow rate of 50 μl/min
using various concentrations of FGF1 ligand (J.K.H. Laboratory)
and IIIa–TM proteins diluted in HBS-EP. Residual bound
FGF and IIIa–TM were removed with injections of 2 M NaCl
and 10 mM HCl. Reference responses from 3CFc flow cells were
subtracted for each analyte concentration using BiaEvaluation
software (BIAcore). Disturbances at the start and end of the
sensorgrams were excluded from curve fitting analysis. Kinetic
and Req (RUs coresponding to steady-state equilibrium) data
were derived using four different analyte concentrations and a
Langmuir model of binding (1:1) for curve fitting. Following
curve fitting, each sensorgram was manually examined for the
closeness of the fit. χ 2 was <10% of Rmax (Rmax, maximum analyte
binding capacity) in all cases.
Chick embryo manipulations and in situ hybridization
The somites of Hamburger and Hamilton stage 17–21 chick
embryos were electroporated with 2 mg/ml of purified plasmids
encoding IIIa–TM or GFP (green fluorescent protein; as control)
using a protocol described previously [26]. After incubation
for 5–7 h of at 37 ◦C, electroporated embryos were fixed
in 4% PFA (paraformaldehyde) and processed for in situ
hybridization using Dig (digoxygenin)- or FL (fluorescence)-
tagged antisense Mkp3 or GFP riboprobes. The in situ signal
was detected using AP (alkaline phosphatase)-tagged anti-
Dig and anti-FL antibodies [26]. GFP was visualized in
orange by using an INT (2-p-iodophenyl-3-p-nitrophenyl-5-
phenyltetrazolium chloride)/BCIP (5-bromo-4-chloroindol-3-yl
phosphate) solution, whereas Mkp3 was visualized in purple
with NBT (Nitro Blue Tetrazolium)/BCIP solutions (Roche; see
Figure 5C). Use of control sense labels did not yield any signal.
RESULTS
Widespread expression and persistence of IIIa–TM in
FgfR2-IIIc+ / tissues
Splicing of FGFR2 exon 7 (IIIa) into 10 (TM) should yield
a 317 amino-acid-long soluble FGFR2 molecule (IIIa–TM;
Figure 1A) with a predicted molecular mass of 35.5 kDa (if non-
glycosylated) and pI of 5.88. In order to contribute to FgfR2-
IIIc+ / (subsequently referred to as ‘mutant’) phenotypes, IIIa–
TM should survive NMD and be detectable at both the transcript
and protein levels.
Using standard RT–PCRs and primers specific to exons 7 (IIIa)
and 10 (TM) respectively, we detected low levels of IIIa–TM
spliced transcripts in RNA derived from the brains of mutant
but not wild-type mice (Figure 1B). To examine whether IIIa–
TM was present as a ‘full-length’ FGFR2 molecule, we used
primers from FGFR2 exon 2 and the IIIa–TM splice junction,
and successfully amplified an 873 bp ‘full-length’ transcript.
DNA sequencing confirmed that this product encodes Ig-I, the
‘acid-box’, Ig-II and Ig-IIIa, spliced to the first nine bases
of exon 10 (Supplementary Figure S1). IIIa–TM transcripts
were found in diverse tissues and all stages examined, namely
in the mutant embryonic forebrain [E (embryonic day) 14.5],
hindbrain (E9.5), lungs (E14.5) and newborn lung, liver and
kidneys, but never in comparable wild-type siblings (results not
shown).
To examine whether the IIIa–TM transcripts are translated
into protein in vivo, we subjected the soluble fraction of protein
isolated from wild-type and mutant tissues to two-dimensional
gel analysis over a pI range of 4–7, and probed the resulting
blots with antibodies that only detect the ectodomain of FGFR2
[the anti-FGFR2(Nt) antibody]. Two major immunoreactive spots
of apparent molecular mass of 55 kDa (pI 5.1 and 6.3) and
a minor 120 kDa spot (pI 4.3) were detectable in the mutant
(Figure. 1C), but not wild-type samples. Equal loading of protein
in these assays was confirmed by anti-tubulin labelling (results not
shown).
Taken together, these findings demonstrate that IIIa–TM is
present and could modulate FGF signalling in the mutant
tissues.
Biochemical characterization of recombinant IIIa–TM protein
To explore the biochemical and binding properties of IIIa–
TM, we generated a recombinant protein. Using RT–PCR, we
first amplified a 0.87 kb IIIa–TM cDNA fragment lacking the
endogenous FGFR2 signal sequence, and cloned this into an ires-
Topaz-pEF-BOS plasmid, downstream of sequences composed
of human FGFR2 secretory signal sequence, human IgG-Fc
and a 3C-protease-sensitive site (Figure 2A and Supplementary
Figure S2). The resulting recombinant protein (subsequently
termed IIIa–TM–3CFc) was isolated from the supernatant
of transiently transfected HEK-293T cells using Protein A–
Sepharose (Figure 2B). The recombinant IIIa–TM protein was
produced optimally at 60 h post-transfection, but thereafter it was
down-regulated or degraded (results not shown).
To further characterize soluble IIIa–TM, the Fc domain
of recombinant IIIa–TM–3CFc was cleaved by 3C protease
digestion. We found that in solution the 3C-cleaved IIIa–TM
protein formed multiple higher molecular-mass products (e.g.
110 kDa) (Figure 2C), which, in the presence of the reducing
agent DTT (200 mM), were reduced to a multiple immunoreactive
species of approximately 55 kDa (Figure 2C, lane 2). Probably,
these higher-order products result from dimeric or oligomeric
association of the native ∼55 kDa protein, via disulfide bonding
c© The Authors Journal compilation c© 2011 Biochemical Society
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Figure 2 Generation and biochemical characterization of recombinant IIIa–
TM protein
(A) The recombinant IIIa–TM protein was fused to the IgG-Fc domain to aid in the purification
process and carries a 3C-protease-sensitive site (arrow head) to allow cleavage of the IgG-Fc
domain. (B) Recombinant 3CFc–IIIa–TM was optimally detected in the supernatant of HEK-293T
cells at 60 h post-transfection. (C) SDS/PAGE analysis of purified IIIa–TM protein revealed
distinct oligomeric complexes of 55–200 kDa under non-reducing conditions (NR). Under
reducing conditions (R), a single ∼50 kDa product was detected, which was reduced further to
∼35 kDa after deglycosylation by PNGase-F treatment (R + P; lane 3). (D) Two-dimensional
gel analysis over the pI range 4–7 revealed that HEK-293T-cell-expressed IIIa–TM can exist in
multiple glycosylated forms in the range of 55–60 kDa.
of the unpaired cysteine residue present on the IgIII domain of
IIIa–TM (Figure 2A), as observed in soluble FGFR1 and FGFR3
molecules [17,27].
IIIa–TM contains eight putative N-glycosylation sites
(Figure 1A and Supplementary Figure S1), a subset of which
must be glycosylated if IIIa–TM, like other FGFRs, is to
interact with FGF ligands. To test this, we removed the N-linked
oligosaccharide residues from 3C-cleaved IIIa–TM by PNGase-F
treatment and found that the apparent mass of the native protein
was reduced from 55 to 35 kDa (Figure 2C, lane 3). Moreover,
resolution of HEK-293T cell-derived recombinant IIIa–TM on
two-dimensional gels yielded eight distinct products of different
molecular masses and pIs (Figure 2D), suggesting that these
are multiple order glycoforms. These findings can explain why
IIIa–TM appears as a broad band on a standard SDS/PAGE gel
(Figure 2C, lane 2) and also raise the possibility that the two spots
observed in Figure 1(C) represent two different glycoforms of
IIIa–TM in the mutant brain in vivo.
IIIa–TM can modulate the binding kinetics of FGF1 to FGFR2
molecules
As a secreted truncated receptor, IIIa–TM could interfere with
FGFR2 signalling either by sequestering FGF ligands away from
FGFRs and/or forming non-functional heterodimers with full-
length FGFRs themselves. However, both of these processes
require an interaction between FGF ligand(s) and IIIa–TM.
We therefore used the well-characterized BIAcore assay [28]
to investigate the dynamics of such interactions, either in the
presence or absence of recombinant FGFR2-IIIb or FGFR2-IIIc
ectodomain molecules.
First, a series of Fc-tagged proteins were generated in HEK-
293T cells by transfection with plasmids encoding IIIa–TM–
3CFc, FGFR2-IIIb–3CFc, FGFR2-IIIc–3CFc or 3CFc as control.
Purified proteins were immobilized on to a BIAcore C1 sensor
chip in equimolar amounts and then different concentrations of
FGF1 were perfused across the sensor chip in the absence of
heparin in order to examine receptor–ligand interactions. FGF1
was chosen because it interacts with all FGFRs/FGFR isoforms
[16]. BIAcore assays measure the rate of association followed
by dissociation of free and chip-anchored proteins. To evaluate
these parameters, we obtained the plasmon resonance values and
normalized them against values obtained by binding of FGF1 to
the control protein 3CFc.
As shown in Figure 3 and Table 1, FGF1 bound chip-anchored
FGFR2-IIIb and FGFR2-IIIc molecules with similar affinity
(Kd = 5.14 × 10− 10 and 7.05 × 10− 10 respectively), but showed
no discernible binding to chip-anchored IIIa–TM (Figure 3D).
The latter observation is probably explained by the absence of the
C-terminal half of the Ig-III-like domain from IIIa–TM [29].
In the presence of excess free IIIa–TM (i.e. 62.5 nM), however,
FGF1 interacted with chip-anchored IIIa–TM (Kd = 6.8 ×
10− 8). Free IIIa–TM also caused more total protein interaction
with chip-anchored FGFR2-IIIb and FGFR2-IIIc (Figures 3G–
3I), but simultaneously reduced the binding affinity of FGF1 to
chip-anchored FGFR2-IIIb and FGFR2-IIIc by 5- and 10-fold
respectively (Table 1). Importantly, we found that, in the absence
of FGF1, excess free IIIa–TM did not bind to chip-anchored IIIa–
TM, FGFR2-IIIb or FGFR2-IIIc (Figures 3A–3C).
Taken together, these findings demonstrate that, as a complex,
IIIa–TM is capable of interacting with FGF1 and modulating
its interactions with receptor molecules that contain the
entire ligand-binding domain. By inference, IIIa–TM may
attenuate FGF signalling through two mutually non-exclusive
mechanisms: sequestering FGF ligands and/or forming non-
functional heterodimers with FGFRs.
Exogenous IIIa–TM modulates the levels of FGFR signalling and
trafficking of FGFR2
We next examined whether IIIa–TM alters the dynamics of FGFR
signalling in cultured cells. Cos7 cells, which endogenously
express the IIIc of FGFR1, FGFR2 and FGFR4 (Figure 4A)
and FGF4 and FGF9 (M.K. Hajihossenini and L.M. Wheldon,
unpublished work), were grown to confluency and serum-starved
before being co-stimulated with FGF2 (20 ng/ml) and heparin
(10 μg/ml), in the presence or absence of exogenously added
3C-cleaved IIIa–TM (5 μg/ml). Immunoblotting of total cell
lysates with anti-ERK and phospho-ERK antibodies showed
that the presence of IIIa–TM reduced the level of FGF
signalling (Figure 4B). Immunoprecipitation of FGFR2 with
antibodies against the cytoplasmic domain of FGFR2 (Bek;
C17), followed by immunoblotting with anti-FGFR2(Nt) or
anti-phosphotyrosine (phospho-Tyr20/4G10 cocktail) antibodies,
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Figure 3 Binding kinetics of recombinant IIIa–TM to FGF1
Sensograms depicting the SPR analysis of FGF1 binding to immobilized 3CFc–IIIa–TM, 3CFc–FGFR2-IIIb and 3CFc–FGFR2-IIIc ectodomains in the absence (D–F) or presence (G–I) of free
IIIa–TM. (A–C) Negligible binding of IIIa–TM alone to these ectodomains was observed. Boxes indicate the concentrations of IIIa–TM and FGF1 applied in each setting. Higher RUs (vertical axis)
observed in (G–I), in the presence of excess IIIa–TM (62.5 nM), indicated that there was a net increase in interaction of FGF1 with the immobilized FGFR molecules. The corresponding kinetic data
are summarized in Table 1. (J) Determination of theoretical Req values for FGF1–FGFR2 binding using four different analyte concentrations (boxes, 6.25–50 nM) and a Langmuir (1:1) model of
binding for curve fitting. Values are means+−S.E.M. of duplicates on the same chip and represent results from three separate chips.
revealed a clear inhibition of FGFR phosphorylation levels in the
presence of IIIa–TM (Figure 4C).
Interestingly, we observed a decrease in levels of full-length
FGFR2 in cells exposed to IIIa–TM and FGF2 combined
(Figure 4C). This could be explained either by rapid destruction
of FGFRs or, more likely, the translocation of FGFRs into a
cellular compartment that is detergent-insoluble or inaccessible to
the immunoprecipitating antibodies. Nonetheless, these changes
demonstrate that exogenously added IIIa–TM can modulate
FGFR2-mediated signalling levels in cultured cells.
To investigate how IIIa–TM has an impact on the trafficking
of FGFR2 in cells, we transfected HEK-293T or Cos7 cells,
which have low levels of endogenous FGFR2, with full-length
FGFR2-encoding plasmids before treatment with exogenous
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Figure 4 Exogenous IIIa–TM modulates the dynamics of FGFR signalling
in HEK-293T cells
(A, upper panel) RT–PCR analysis using isoform-specific primers [20] showing that IIIc isoforms
of FGFR1 and FGFR2 predominate in HEK-293T cells. This was confirmed further for FGFR2
(lower panel) as RT–PCR-amplified IIIa–IIIb–TM and IIIa–IIIc–TM products using common
primers from FGFR2 IIIa and TM exons were digested by the EcoRV, but not the AvaI, enzyme
[34]. (B) Stimulation of HEK-293T cells with the cognate ligand (FGF2) induced a time-dependent
ERK activation in control cells (lower panel, lanes 1–3), which was attenuated by exogenous
IIIa–TM (lower panel, lanes 4–6). Results are representative of three independent experiments.
(C) Analysis of immunoprecipitated FGFR2 shows a marked reduction in the level of receptor
tyrosine phosphorylation in the presence of IIIa–TM after both 5 and 30 min of FGF2 stimulation.
IP, immunoprecipitation; IB, immunoblotting.
IIIa–TM in the presence or absence of FGF2 (Figure 5A).
Co-immunolabelling of cells with anti-FGFR2(Nt) and anti-
Lamp2 antibodies and quantification of their co-localization
showed that, in the absence of IIIa–TM, significant levels
of transfected FGFR2 was internalized into Lamp2-positive
late endosomes and lysosomes, even when cells were treated
with FGF2. In the presence of IIIa–TM, however, FGFR2
molecules appeared to accumulate at the cell membrane, more
so when FGF2 was present, and showed reduced association with
endosomes/lysosomes (Figures 5B–5H). These findings concur
with the BIAcore data and suggest that IIIa–TM forms a complex
with FGF ligands and receptors, which, in living cells, traps the
receptors at the cell surface.
IIIa–TM can attenuate FGF signalling in vivo
Next, we tested whether IIIa–TM can also modulate FGFR
signalling in vivo in chick embryos. We took advantage of previous
findings that proper generation of chick somites (precursors
to axial muscles) relies on FGFR signalling [26], such that
electroporation of a dominant-negative (membrane-bound) FGFR
construct or the application of the FGFR inhibitor SU5406 can
disrupt normal somitogenesis. Attenuation of FGF signalling in
this system is measured by the loss of Mkp3 expression, which
is a cytoplasmic modulator and a target of FGFR signalling itself
[10,26].
Plasmids encoding IIIa–TM (2 μg/ml) or GFP were
electroporated into the developing chick somites and in situ
hybridization was used to detect GFP or Mkp3 in the manipulated
embryos (n = 2 of each treatment). As shown in Figure 6,
introduction of IIIa–TM- but not GFP-encoding plasmids resulted
in the loss of Mkp3 expression, which is reminiscent of the
attenuation of FGFR signalling by SU5402 or dominant-negative
FGFRs [26]. These findings demonstrate that IIIa–TM interferes
with FGFR signalling in an in vivo setting.
DISCUSSION
In the present study we show that a soluble FGFR2 molecule
is up-regulated in FgfR2-IIIc+ / mice, which model AS. We
termed this molecule IIIa–TM, as it arises from aberrant splicing
of FGFR2 exon 7 (IIIa) into exon 10 (TM). Neither the transcript
nor IIIa–TM protein were detected in wild-type tissues/cells.
Recombinant IIIa–TM generated in HEK-293T cells was found to
be N-glycosylated and formed oligomeric complexes in solution.
Using BIAcore sensor chip assays we found that IIIa–TM protein
displays limited FGF ligand binding. Exogenous addition of IIIa–
TM in the presence of FGF ligands efficiently attenuated FGFR
signalling and interfered with receptor trafficking in cultured
cells. Finally, introduction of IIIa–TM into the developing chick
embryos attenuated FGFR signalling. Taken together, these
findings suggest that IIIa–TM is in a position to induce loss-
of-FGFR signalling in FgfR2-IIIc+ / mice and, by inference, in
AS.
FGFR2 is encoded by 19 exons that can generate a spectrum
of alternatively spliced transcripts [7]. IIIa–TM is one such
candidate, but it was not detected in normal cells either by RT–
PCR (the present study) or RNAse protection assays [30]. This
suggests that either splicing of exon 7 into 10 is a rare event
or, more likely, that, as a PTC-containing transcript, IIIa–TM
is normally destroyed by components of the NMD pathway. In
general, the NMD machinery eliminates transcripts that carry a
PTC positioned greater than 50–55 bp upstream of the last coding
splice junction of a gene (for reviews, see [19,31]).
Interestingly, NMD is thought to play a critical role in regulating
the expression levels of alternatively spliced genes, whereby the
amount of useful transcripts destined for translation is titrated
through active production and destruction of related PTC-
harbouring transcripts [32,33]. Therefore IIIa–TM transcripts
could play important role(s) in regulating the normal level
of FGFR2 expression and signalling. However, when such
transcripts persist, as in disease situations, they could assume
entirely different regulatory roles.
It is not clear how and why IIIa–TM escapes NMD in FgfR2-
IIIc+ / tissues, but it is not a peculiarity of this allele as it can be
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Table 1 Summary of kinetic data for FGF1 binding in the absence or presence of a 10-fold excess of soluble IIIa–TM
K on and K off were derived as described in the Materials and methods section. χ 2 was <10 % of Rmax in all cases. The apparent affinity, K d, is equal to K off/K on. NDB, no discernable binding.
Analyte bound to C1 sensor chip (value by receptor isotype)
Soluble analyte Parameter IIIa–TM–Fc FGFR2-IIIb–Fc FGFR-2IIIc–Fc
FGF1 K on (M− 1 · s− 1) NDB 3.93 × 106 2.41 × 106
K off (s− 1) NDB 2.02 × 10− 3 1.70 × 10− 3
K d (M) NDB 5.14 × 10− 10 7.05 × 10− 10
FGF1 + IIIa–TM K on (M− 1 · s− 1) 1.77 × 105 3.48 × 105 2.75 × 105
K off (s− 1) 1.20 × 10− 2 1.00 × 10− 3 2.00 × 10− 3
K d (M) 6.80 × 10− 8 2.87 × 10− 9 7.27 × 10− 9
Figure 5 Exogenous IIIa–TM interferes with trafficking of FGFR2
(A) Experimental paradigm and time-course of analysis. (B–G) Differential localization of FGFR2 in transfected Cos7 cells after their stimulation with exogenous FGF2 (20 ng/ml), heparin (10 μg/ml)
and IIIa–TM (5 μg/ml). In untreated or cells stimulated with FGF2 or IIIa–TM alone, FGFR2 co-localized with late endosomes, marked by Lamp2 expression (open arrows in B–E). Combined
FGF2 and IIIa–TM treatment, however, appeared to trap much of the transfected FGFR2 at the cell membrane and reduce its co-localization with endosomal compartment (closed arrows in F and
G). Results are representative of three separate experiments. Scale bars, 10 μm. (H) Quantification of FGFR2/Lamp2 co-localization coefficient (see the Materials and methods section) shows a
significant reduction in transfected cells treated with IIIa–TM when compared with its absence. Values are means +− S.E.M., n15 from two independent experiments. *P < 0.05 and ***P <
0.0001.
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Figure 6 IIIa–TM attenuates FGFR signalling in vivo
(A) Photomicrograph of a chick embryo highlighting the region that was electroporated at
stage 17 of chick embryonic development. (B and C) A clear down-regulation of MKP3 gene
expression (purple stain) was observed following electroporation of embryos with IIIa–TM (B),
but not GFP-encoding control plasmids (C). The brown stain in (C) is in situ hybridization stain
for GFP to show the comparable domain of GFP transduction.
detected in two other in vivo settings involving perturbed FGFR2
signalling. These are: (i) in FgfR2-IIIb-null mice, which lack
both copies of exon 8 (IIIb) and are deficient in epithelial FGFR2
signalling [34]; and (ii) in some Pfeiffer syndrome patients who
carry a mutation close to the splice acceptor site of FGFR2
exon 9 (IIIc), the mesenchymal isoform, and manifest cranial and
limb phenotypes [35]. The NMD pathway is not totally efficient
[31] and it is possible that, in the above scenarios, IIIa–TM is
overexpressed above a threshold that NMD components, such
as the Upf1 enzyme, can deal with. Indeed, loss of Upf1 leads
to persistence of PTC-containing transcripts [33]. However, the
observed up-regulation of IIIa–TM following perturbed FGFR2
signalling in multiple settings and tissue compartments suggests
that FGFR2 signalling itself somehow has an impact on the
activity of the NMD machinery to result in the stabilization of
IIIa–TM and possibly other PTC-containing transcripts.
Bioavailability of ligands is a key regulator of paracrine cell
signalling levels and can be controlled through sequestration
of ligands by soluble proteins. For example, the levels
of EGF (epidermal growth factor) and Wnt signalling are
controlled in part by the naturally occurring extracellular proteins
Argos [36] and Frizzled-related proteins [37] respectively.
Experimental overexpression of soluble FGFR2-IIIb in mice
yields phenotypes that are reminiscent of loss of FGFR2-
IIIb or FGF10 genes themselves [1,34,38]. Indeed, soluble
receptors are more potent than dominant-negative membrane-
anchored receptors in attenuating FGF signalling [38]. Therefore
IIIa–TM may attenuate FGFR signalling by sequestering FGF
ligands away from membrane-anchored FGFRs and/or by forming
non-functional heterotrimers with FGFRs and FGF ligands.
Furthermore, the latter may interfere with normal trafficking
of FGFRs, as suggested by our immunolabelling studies in
Figure 5.
The inhibitory effects of IIIa–TM may depend on its
glycosylation and interaction with FGF ligands. IIIa–TM carries
eight putative glycoyslation sites and our present findings suggest
that these are glycosylated in multiple orders in vitro (Figure 2C)
and in vivo (Figures 1C and 2D). Delineating the exact type and
pattern of glycosylation of these species may shed more light on
its functions, since glycosylation of distinct residues on FGFRs
can differentially promote or reduce their association with FGF
ligands [39,40].
Our present BIAcore results show that, through an association
with FGF1, soluble IIIa–TM forms a heterotrimeric complex
with both IIIb and IIIc isoforms of FGFR2. We used FGF1,
a pan-FGFR-activating ligand, in these assays, but it would
be informative to determine whether IIIa–TM preferentially
associates with distinct FGF ligands as seen in truncated
soluble FGFR1 molecules [17]. Our present results indicate
that IIIa–TM can interact with IIIc-activating ligands and
possibly even interferes with other FGFR subtypes. Notably,
IIIa–TM attenuates FGFR signalling in HEK-293T cells in the
presence of FGF2, in a system where FGF4 and FGF9 are the
only other endogenously produced FGFs (L.M. Wheldon and
M.K. Hajihosseini, unpublished work). Furthermore, IIIa–TM
attenuates FGF signalling in developing chick somites, which
is dependent on FGF8 to FGFR1 signalling [26].
Relevance to AS and cancer
AS is caused by dominant-acting FGFR2 molecules that operate
entirely in a ligand-dependant manner [6]. AS is hallmarked
by the fusion of craniofacial sutures and by limb abnormalities
accompanied by other sporadic visceral and neural defects [41].
Individuals harbouring the same mutation can present different
levels of phenotypic severity. Although the ethnological origin of
patients is likely to influence the severity of their defects, it is
also conceivable that other modulatory molecules such as IIIa–
TM could contribute to specific defects. Two specific examples
include cleft palate [42] and blind colon [41], phenotypes that are
reminiscent of complete loss of FGF10 or FGFR2-IIIb signalling
in mice [1,43].
How can IIIa–TM induce loss-of-FGFR2 function when
AS-type mutations are thought to act in a gain-of-function
manner? Normally, epithelial and mesenchymal cells engage in
a cross-talk through mutually exclusive expression of FGFR2-
IIIb and FGFR2-IIIc isoforms and their respective activating
ligands (see the Introduction, and Supplementary Figure S3
at http://www.BiochemJ.org/bj/436/bj4360071add.htm). It has
been shown that AS-mutant receptors act predominantly in the
mesenchyme through an illegitimate interaction with FgfR2-IIIb-
activating ligands, such as FGF10 [44]. Thus membrane-anchored
AS-mutant receptors and up-regulated IIIa–TM combined could
compete with epithelially expressed FGFR2-IIIb for its cognate
ligand FGF10 to cause a loss of FGFR2-IIIb function in epithelial
cells. In support of this hypothesis, we have found that reducing
the bioavailability of FGF10 in FgfR2-IIIc+ / mice (i.e. in
FgfR2-IIIc+ / and Fgf10+ / − -double mutants) accentuates this
competition and results in the occurrence of blind colon and cleft
palate in a significant number of double mutants (Supplementary
Figure S3; and [23])
IIIa–TM may not be the only soluble receptor to become
overexpressed in AS patients [45]. Nonetheless, a detailed
survey of these patients for IIIa–TM expression, together
with experimental up-regulation of IIIa–TM in a spatially and
temporally controlled manner in wild-type and mutant mouse
models, would help delineate the roles we have postulated in the
present study.
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Soluble FGFRs have been also been isolated from a variety
of tumour cells [46–49]. Interestingly, a Pfeiffer-syndrome-type
FGFR2 mutation that causes IIIa–TM up-regulation (described
above) [35] is also the cause of colorectal cancer [50]. It
is not clear whether expression of soluble receptors such as
IIIa–TM are the cause or the consequence of cancer, but our
characterizations suggest that IIIa–TM is likely to act as an
inhibitor of FGFR signalling in the context of tumorigenesis.
It is interesting to note then that loss-of-FGFR2 function has been
associated with specific types of astrocytomas and bladder cancers
[51,52].
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Figure S1 Nucleotide sequence of 873 bp ‘full-length’ IIIa–TM amplified
by RT–PCR using primers P3 and P4
Colour coding is indicated on the Figure.
Figure S2 Schematic representation of the ires-Topaz-PEF-BOS plasmid
into which the ss-3C-FC-IIIa–TM fragments were cloned as an NdeI/NotI
0.87 kb fragment
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Figure S3 A hypothetical scenario by which IIIa–TM induces loss-of-FGFR2 function
IIIa–TM competes with membrane-bound receptors for FGF ligand(s) following its up-regulation in FgfR2-IIIc+ / mice. In (C), a heterozygous reduction in FGF10 may accentuate this competition
and result in loss-of-FGF10-to-FGFR2-IIIb signalling in epithelial cells. Yellow, normal level of FGFR2 signalling in either epithelial or mesenchymal cells in wild-type tissues; red circles,
FGFR2-IIIc-activating ligands produced by epithelial cells; navy blue circles, FGFR2-IIIb-activating ligands produced by mesenchymal cells; red and blue Ig-III-like domains, FGFR2-IIIc and
FGFR2-IIIb respectively; orange, elevated levels of FGFR2 signalling in mesenchymal cells of FgfR2-IIIc+ / mice, as a result of FGFR2-IIIb up-regulation and autocrine signalling. Truncated
receptors, IIIa–TM.
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